search for




 

Review Article
Progress of Hemophilia A Therapeutics in Korea
Clin Pediatr Hematol Oncol 2018;25:17-22.
Published online April 30, 2018
© 2018 Korean Society of Pediatric Hematology-Oncology and Korean Society for Pediatric Neuro-Oncology

Dong Hyun Kim, M.D., Soon Ki Kim, M.D., Ph.D

Department of Pediatrics, College of Medicine, Inha University, Incheon, Korea
Correspondence to: Soon Ki Kim
Department of Pediatrics, College of Medicine, Inha University Hospital, 27 Inhang-ro, Jung-gu, Incheon 22332, Korea
Tel: +82-32-890-2843 Fax: +82-32-890-2844 E-mail: pedkim@inha.ac.kr
Received March 28, 2018; Revised April 5, 2018; Accepted April 18, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Over the past several decades, hemophilia treatment in Korea has progressed dramatically. It has become possible to prevent hemophilia complications by maintenance treatment as well as on-demand treatment with the help of the National Health Insurance program. Treatment and prevention of hemorrhage, prevention of joint complications, treatment and prevention of infectious complications have greatly improved the quality of life and life expectancy of hemophilia patients. However, the development of inhibitor is the most serious and challenging complication of clotting factor replacement therapy, although immune tolerance regimens and bypassing agents have shown some efficacy in countering this complication. The development of novel methods of therapy, including the use of extended half-life factors and gene therapy, will further improve the outcome of hemophilia patients. Administering the right drug to the right patients with the right dose at the right time will be necessary for treating the patient. Achievement of optimal therapeutic goals will require continued cooperation between patients and medical staff.
Keywords: Factor VIII, Hemophilia A, Recombinant factor VIII, Inhibitor
References
  1. Korea Hemophilia Foundation. 2015 Annual report Korea Hemophilia Foundation. Seoul, Korea: Korea Hemophilia Foundation, 2016. (Accessed March 1, 2018, at http://www. kohem.org/_data/board_list_file/8/2016/1608121506441.pdf)
  2. Kim EJ, Lee H. Current status and comprehensive care of Korean hemophiliacs. Korean J Hematol 2000;35:222-32.
  3. Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976;65:129-35.
    Pubmed CrossRef
  4. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357: 535-44.
    Pubmed CrossRef
  5. Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014;12:1935-9.
    Pubmed CrossRef
  6. Choi EJ. Management of hemophilia in Korea: the past, present, and future. Blood Res 2014;49:144-5.
    Pubmed KoreaMed CrossRef
  7. Kim DH, Kim SK, Park SK, Yoo KY, Hwang TJ, Choi YM. Korea Hemophilia Foundation registry trends 1991-2012: patient registry, demographics, health services utilization. Haemophilia 2015;21:e479-80.
    Pubmed CrossRef
  8. Mannucci PM. Modern treatment of hemophilia: from the shadows towards the light. Thromb Haemost 1993;70:17-23.
    Pubmed
  9. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008;14 Suppl 3:10-8.
    Pubmed CrossRef
  10. Ramgren O. A clinical and medico-social study of haemophilia in Sweden. Acta Med Scand Suppl 1962;379:111-90.
    CrossRef
  11. Rizza CR, Spooner RJ. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom. Br Med J (Clin Res Ed) 1983;286:929-33.
    CrossRef
  12. Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976;65:129-35.
    Pubmed CrossRef
  13. Centers for Disease Control (CDC). Pneumocystis carinii pneumonia among persons with hemophilia A. MMWR Morb Mortal Wkly Rep 1982;31:365-7.
    Pubmed
  14. Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220: 868-71.
    CrossRef
  15. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984;224:500-3.
    Pubmed CrossRef
  16. Cho YK, Jung YS, Foley BT. Phylogenetic analysis of full-length pol gene from Korean hemophiliacs and plasma donors infected with Korean subclade B of HIV type 1. AIDS Res Hum Retroviruses 2011;27:613-21.
    Pubmed CrossRef
  17. Mannucci PM. The choice of plasma-derived clotting factor concentrates. Baillieres Clin Haematol 1996;9:273-90.
    CrossRef
  18. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347:921-5.
    CrossRef
  19. Yoon HJ, Lee SY, Hwang TJ, Sohn YT. A prospective study on the pharmacokinetics of monoclonal-antibody-purified factor VIII concentrate (GreenMono(R)) in previously treated subjects with hemophilia A. Korean J Hematol 2001;36: 148-53.
  20. Stenland CJ, Lee DC, Brown P, Petteway SR Jr, Rubenstein R. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. Transfusion 2002;42:1497-500.
    Pubmed CrossRef
  21. White GC 2nd, McMillan CW, Kingdon HS, Shoemaker CB. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989;320:166-70.
    Pubmed CrossRef
  22. Josephson CD, Abshire T. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement? Clin Adv Hematol Oncol 2004;2:441-6.
    Pubmed
  23. Björkman S, Blanchette VS, Fischer K, et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 2010;8:730-6.
    CrossRef
  24. Lee DC, Miller JL, Petteway SR Jr. Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE Bayer. Haemophilia 2002;8 Suppl 2:6-9.
    Pubmed CrossRef
  25. Gomperts E, Lundblad R, Adamson R. The manufacturing process of recombinant factor VIII, recombinate. Transfus Med Rev 1992;6:247-51.
    CrossRef
  26. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci U S A 1986;83:5939-42.
    Pubmed KoreaMed CrossRef
  27. Kelley BD, Tannatt M, Magnusson R, Hagelberg S, Booth J. Development and validation of an affinity chromatography step using a peptide ligand for cGMP production of factor VIII. Biotechnol Bioeng 2004;87:400-12.
    Pubmed CrossRef
  28. Han H, Shin KH, Paik SH, et al. Pharmacokinetics and tolerability evaluation of human coagulation recombinant factor VIII (GreenGene(TM)) in hemophilia A patients. J Korean Soc Clin Pharmacol Ther 2011;19:144-51.
  29. Paik SH, Kim YJ, Han SK, Kim JM, Huh JW, Park YI. Mixture of three amino acids as stabilizers replacing albumin in lyophilization of new third generation recombinant factor VIII GreenGene F. Biotechnol Prog 2012;28:1517-25.
    Pubmed CrossRef
  30. Kim SK, Yoo KY, Lee KS, et al. Safety and efficacy of b-domain deleted third generation recombinant factor VIII (GreenGene F™) in Korean patients with hemophilia A: data from a post-marketing surveillance study. J Korean Med Sci 2018;33:e5.
    Pubmed KoreaMed CrossRef
  31. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007;109:4648-54.
    Pubmed CrossRef
  32. Martinowitz U, Bjerre J, Brand B, et al. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE?)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia 2011;17:854-9.
    Pubmed CrossRef
  33. Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol 2012;81:82-93.
    Pubmed CrossRef
  34. Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013;368:231-9.
    Pubmed CrossRef
  35. Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003;102:2358-63.
    Pubmed CrossRef
  36. Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood 2012;120:720-7.
    Pubmed CrossRef
  37. Franchini M, Lippi G. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review. Thromb Haemost 2010;104:931-40.
    Pubmed CrossRef
  38. Navarrete AM, Dasgupta S, Teyssandier M, et al. Endocytic receptor for pro-coagulant factor VIII: relevance to inhibitor formation. Thromb Haemost 2010;104:1093-8.
    Pubmed CrossRef
  39. Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016;374:2054-64.
    Pubmed CrossRef
  40. Yoo KY, Choi YM, Hwang TJ, Choi EJ. The efficacy of prophylaxis for children with severe hemophilia in Korea -an experience of single institute. Clin Pediatr Hematol Oncol 2012;19:79-85.
  41. Yoo KY, Kim SK, Kwon SS, et al. Life expectancy of Korean haemophiliacs, 1991-2012. Haemophilia 2014;20:e356-8.
    Pubmed CrossRef
  42. Oldenburg J, Albert T. Novel products for haemostasis - current status. Haemophilia 2014;20 Suppl 4:23-8.
    Pubmed CrossRef
  43. Nathwani AC, Davidoff AM, Tuddenham EGD. Gene therapy for hemophilia. Hematol Oncol Clin North Am 2017;31: 853-68.
    Pubmed CrossRef


October 2018, 25 (2)
Full Text PDF
Citation
Send to a friend
Twitter
Facebook

Cited By Articles
  • CrossRef (0)

Author ORCID Information
  • Soon Ki Kim